Mercury II - Compare the Efficacy and Safety of Lipid Lowering Agents Atorvastatin and Simvastatin With Rosuvastatin in High Risk Subjects With Type IIa and IIb Hypercholesterolemia
Phase 3
Completed
- Conditions
- Hypercholesterolemia
- Interventions
- Registration Number
- NCT00654407
- Lead Sponsor
- AstraZeneca
- Brief Summary
The purpose of this study is to determine whether treatment with rosuvastatin following atorvastatin or simvastatin treatment will improve health outcomes for patients at high risk of Coronary heart disease compared to atorvastatin and simvastatin alone.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 4875
Inclusion Criteria
- Discontinuation of all cholesterol lowing drugs, including dietary supplements.
- Documented history of, or high risk of coronary heart disease or other established atherosclerotic disease.
Exclusion Criteria
- The use of lipid lowering drugs or dietary supplements after Visit 1.
- Active arterial disease eg Unstable angina, or recent arterial surgery
- Uncontrolled hypertension, hypothyroidism, alcohol or drug abuse.
- Abnormal laboratory parameters as defined in the protocol.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description 3 Simvastatin Simvastatin 2 Atorvastatin Atorvastatin 1 Rosuvastatin Rosuvastatin
- Primary Outcome Measures
Name Time Method Low density Lipoprotein cholesterol level - reaching internationally recognised LDL cholesterol goal levels. 16 weeks
- Secondary Outcome Measures
Name Time Method Percentage change in other cholesterol & triglyceride measures 16 weeks Safety evaluation 8 & 16 weeks To compare the efficacy of rosuvastatin with atorvastatin and simvastatin